140 related articles for article (PubMed ID: 38081200)
81. Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography.
Oba A; Mise Y; Ito H; Hiratsuka M; Inoue Y; Ishizawa T; Arita J; Matsueda K; Takahashi Y; Saiura A
HPB (Oxford); 2018 Aug; 20(8):708-714. PubMed ID: 29534862
[TBL] [Abstract][Full Text] [Related]
82. Quantitative margin assessment of radiofrequency ablation of a solitary colorectal hepatic metastasis using MIRADA RTx on CT scans: a feasibility study.
Sibinga Mulder BG; Hendriks P; Baetens TR; van Erkel AR; van Rijswijk CSP; van der Meer RW; van de Velde CJH; Vahrmeijer AL; Mieog JSD; Burgmans MC
BMC Med Imaging; 2019 Aug; 19(1):71. PubMed ID: 31429708
[TBL] [Abstract][Full Text] [Related]
83. Detection and Viability of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Multiparametric PET/CT-MRI Study.
Dunet V; Halkic N; Prior JO; Anaye A; Meuli RA; Sempoux C; Denys A; Schmidt S
Clin Nucl Med; 2017 Apr; 42(4):258-263. PubMed ID: 28166142
[TBL] [Abstract][Full Text] [Related]
84. Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.
Kim YK; Park G; Kim CS; Yu HC; Han YM
Br J Radiol; 2012 May; 85(1013):539-47. PubMed ID: 22556405
[TBL] [Abstract][Full Text] [Related]
85. Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.
Orlacchio A; Chegai F; Fabiano S; Merolla S; Funel V; Di Giuliano F; Manuelli M; Tisone G; Francioso S; Angelico M; Palmieri G; Simonetti G
Radiol Med; 2016 Jul; 121(7):588-96. PubMed ID: 27100719
[TBL] [Abstract][Full Text] [Related]
86. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents.
Mainenti PP; Mancini M; Mainolfi C; Camera L; Maurea S; Manchia A; Tanga M; Persico F; Addeo P; D'Antonio D; Speranza A; Bucci L; Persico G; Pace L; Salvatore M
Abdom Imaging; 2010 Oct; 35(5):511-21. PubMed ID: 19562412
[TBL] [Abstract][Full Text] [Related]
87. The value of a dedicated multidisciplinary expert panel to assess treatment strategy in patients suffering from colorectal cancer liver metastases.
Hellingman T; de Swart ME; Joosten JJA; Meijerink MR; de Vries JJJ; de Waard JWD; van Zweeden AA; Zonderhuis BM; Kazemier G
Surg Oncol; 2020 Dec; 35():412-417. PubMed ID: 33035790
[TBL] [Abstract][Full Text] [Related]
88. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial.
Zech CJ; Justo N; Lang A; Ba-Ssalamah A; Kim MJ; Rinde H; Jonas E
Eur Radiol; 2016 Nov; 26(11):4121-4130. PubMed ID: 26905871
[TBL] [Abstract][Full Text] [Related]
89. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison.
Yoon JH; Lee JM; Lee YJ; Lee KB; Han JK
J Magn Reson Imaging; 2019 Feb; 49(2):574-587. PubMed ID: 30102433
[TBL] [Abstract][Full Text] [Related]
90. A prospective clinical study using a dynamic contrast-enhanced CT-protocol for detection of colorectal liver metastases.
Van Camp L; Deak P; Haspeslagh M; Coenegrachts K
Eur J Radiol; 2018 Oct; 107():143-148. PubMed ID: 30292259
[TBL] [Abstract][Full Text] [Related]
91. Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort.
Seidensticker M; Steffen IG; Bargellini I; Berg T; Benito A; Gebauer B; Iezzi R; Loewe C; Karçaaltincaba M; Pech M; Sengel C; van Delden O; Vandecaveye V; Zech CJ; Ricke J
Curr Oncol; 2022 Jan; 29(2):565-577. PubMed ID: 35200551
[TBL] [Abstract][Full Text] [Related]
92. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
Niekel MC; Bipat S; Stoker J
Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
[TBL] [Abstract][Full Text] [Related]
93. Detection of colorectal liver metastases: prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography.
Lencioni R; Donati F; Cioni D; Paolicchi A; Cicorelli A; Bartolozzi C
MAGMA; 1998 Dec; 7(2):76-87. PubMed ID: 9951768
[TBL] [Abstract][Full Text] [Related]
94. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
[TBL] [Abstract][Full Text] [Related]
95. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases.
Dresen RC; De Vuysere S; De Keyzer F; Van Cutsem E; Prenen H; Vanslembrouck R; De Hertogh G; Wolthuis A; D'Hoore A; Vandecaveye V
Cancer Imaging; 2019 Jan; 19(1):1. PubMed ID: 30616608
[TBL] [Abstract][Full Text] [Related]
96. Small colorectal liver metastases: detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging.
Hekimoglu K; Ustundag Y; Dusak A; Kalaycioglu B; Besir H; Engin H; Erdem O
Eur J Radiol; 2011 Mar; 77(3):468-72. PubMed ID: 19781882
[TBL] [Abstract][Full Text] [Related]
97. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.
Taylor SA; Mallett S; Beare S; Bhatnagar G; Blunt D; Boavida P; Bridgewater J; Clarke CS; Duggan M; Ellis S; Glynne-Jones R; Goh V; Groves AM; Hameeduddin A; Janes SM; Johnston EW; Koh DM; Miles A; Morris S; Morton A; Navani N; O'Donohue J; Oliver A; Padhani AR; Pardoe H; Patel U; Punwani S; Quinn L; Rafiee H; Reczko K; Rockall AG; Shahabuddin K; Sidhu HS; Teague J; Thaha MA; Train M; van Ree K; Wijeyekoon S; Halligan S;
Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):529-537. PubMed ID: 31080095
[TBL] [Abstract][Full Text] [Related]
98. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
99. Liver MRI in patients scheduled for local therapy of colorectal liver metastases.
Vernuccio F
Lancet Oncol; 2024 Jan; 25(1):9-10. PubMed ID: 38081199
[No Abstract] [Full Text] [Related]
100. MRI with gadoxetate disodium for colorectal liver metastasis: is it the new "imaging modality of choice"?
Patel S; Cheek S; Osman H; Jeyarajah DR
J Gastrointest Surg; 2014 Dec; 18(12):2130-5. PubMed ID: 25319036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
